Published in Drug Week, December 18th, 2009
"We studied the prevalence of NAbs in MS patients grouped according to their clinical response to IFN beta during the treatment period. were classified as: group A, developing >= 1 relapse after the first 6 months of therapy; group B, exhibiting confirmed disability progression after the first 6 months of therapy, with or without superimposed relapses; group C,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.